重要的消息有哪些 1．5月8日（周四）申购提示：新股方面，太力科技申购代码301595，发行价17.05元/股，申购上限0.65 万股。威高血净申购代码732014，发行价26.50元/股，申购上限1.10万股。投资有风险，申购需谨慎。 2．国务院新闻办公室将于2025年5月8日（星期四）上午10时举行新闻发布会，请司法部副部长王振江 和全国人大常委会法工委、国家发展改革委、金融监管总局、全国工商联负责人介绍《中华人民共和国 民营经济促进法》有关情况，并答记者问。 3．5月7日，外交部发布消息，何立峰副总理将于5月9日—12日访问瑞士，其间与美方举行会谈。外交 部发言人林剑表示，美方近期不断表示，希望同中方进行谈判。这次会谈是应美方请求举行的，中方坚 决反对美国滥施关税这一立场没有任何变化。同时我们也多次说过，中方对对话持开放态度，但任何对 话都必须建立在平等、尊重、互惠的基础上，任何形式的施压、胁迫，对中国都是行不通的。中方将坚 定维护自身的正当利益，维护国际的公平正义。（央视新闻） 4．中国人民银行7日发布公告，从5月8日起，下调公开市场7天期逆回购操作利率0.1个百分点。自5月 15日起，下调金融机构存 ...

证券研究报告 2025 年 5 月 6 日 星期二 【新股发行跟踪（20250506）】 从周度上市新股表现来看，上上周无新股首日破发。 表 1：周度新股上市概况 | 期间 | | 新股上市数（主 | | 首发募资 | 首日破 | 首日涨超 | 首日涨跌幅范围 | 首日涨跌幅 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 板/双创） | | （亿元） | 发率 | 100%数量 | | 均值 | | | 4-28 | 至 4-30 | 0 | (0/0) | 0.00 | 0% | 0 | (0.00%，0.00%) | 至 4-28 | 4-30 | | 4-21 | 至 4-25 | 3 | (2/1) | 48.02 | 0% | 1 | (24.06%，179.39%) | 至 4-21 | 4-25 | | 4-14 | 至 4-18 | 3 | (2/1) | 11.71 | 0% | 3 | (165.08%，312.58%) | 至 4-14 | 4-18 | | 4-7 至 | 4-11 | 3 ...

Core Viewpoint - Hanbang Technology (688755.SH) is set to launch its IPO on May 7, 2023, with a price of 22.77 yuan per share, which corresponds to a P/E ratio of 26.35, slightly below the industry average of 28.04 and the comparable companies' average of 46.64 [1] Company Overview - Hanbang Technology, established in October 1998, focuses on chromatography technology, providing specialized separation and purification equipment, consumables, and technical solutions for the pharmaceutical and life sciences sectors [3] - The company aims to raise approximately 5.01 billion yuan through the issuance of 22 million shares, with a net fundraising amount expected to be around 4.31 billion yuan after deducting issuance costs [1] Financial Performance - Revenue for Hanbang Technology is projected to grow from 482 million yuan in 2022 to 691 million yuan in 2024, with net profits increasing from approximately 38.56 million yuan to 79.34 million yuan during the same period [3][4] - The gross profit margin is expected to improve from 39.22% in 2022 to 42.46% in 2024 [3] - The company's total assets are projected to decrease from 1.40 billion yuan in 2022 to 1.32 billion yuan in 2024, while the equity attributable to shareholders is expected to rise from 566.92 million yuan to 739.63 million yuan [4] Revenue Composition - The primary revenue sources for Hanbang Technology are small molecule and large molecule drug separation and purification equipment, with small molecule equipment sales increasing from 49.75% of revenue in 2022 to 66.7% in 2024 [5][6] - The revenue from large molecule drug separation equipment is expected to decline from 44.46% in 2022 to 28% in 2024 [6] R&D and Accounts Receivable - R&D expenditures for Hanbang Technology were 28.99 million yuan, 37.18 million yuan, and 41.84 million yuan over the last three years, totaling 108 million yuan, which is 6.03% of cumulative revenue [8] - The accounts receivable at the end of the reporting periods were 131 million yuan, 119 million yuan, and 130 million yuan, with overdue accounts receivable making up a significant portion [8] Market Position and Risks - Hanbang Technology holds the leading market share in the domestic small molecule liquid chromatography system market, reaching 39.2% in 2023, but faces limited room for further growth [9] - The company is involved in ongoing patent infringement lawsuits with Cytiva, which could negatively impact its financial performance if the rulings are unfavorable [9]

Summary of Key Points Core Viewpoint - This week, three new stocks are available for subscription in the A-share market, including Hanbang Technology, Weigao Blood Purification, and Taili Technology [1][2]. Group 1: Hanbang Technology - Hanbang Technology is a leading company in chromatography equipment in China, with a subscription code of 787755 and an issue price of 22.77 yuan per share, with a P/E ratio of 26.35 times [3][6]. - The total number of shares issued is 22 million, with 5.28 million shares available for online subscription. The maximum subscription limit for investors is 5,000 shares, requiring a market value of 50,000 yuan in the Shanghai market [3][6]. - The company’s revenue is projected to grow from 482 million yuan in 2022 to 691 million yuan in 2024, with net profits increasing from 38.56 million yuan to 79.34 million yuan during the same period [7][10]. - Major clients include domestic pharmaceutical companies and international clients such as INTECH ANALYTICAL INSTRUMENTS and REETEC AS [7]. Group 2: Weigao Blood Purification - Weigao Blood Purification is a manufacturer of medical products for blood purification, with a subscription code of 732014. The total number of shares issued is 41.14 million, with 11.11 million shares available for online subscription [12][14]. - The company’s revenue is expected to rise from 3.426 billion yuan in 2022 to 3.604 billion yuan in 2024, with net profits increasing from 315.00 million yuan to 449.39 million yuan [12][14]. - Key clients include major pharmaceutical groups such as China National Pharmaceutical Group and China Resources Group [12]. Group 3: Taili Technology - Taili Technology focuses on new material research and vacuum technology applications, with a subscription code of 301595. The total number of shares issued is 27.07 million, with 6.90 million shares available for online subscription [17]. - The company’s revenue is projected to grow from 638 million yuan in 2022 to 1.020 billion yuan in 2024, with net profits increasing from 58.84 million yuan to 87.64 million yuan [17][18]. - Major clients include international retailers such as IKEA and Walmart, with Taili Technology being the exclusive supplier of vacuum bags for China's aerospace applications [17].

Core Viewpoint - The A-share market will have three new stock subscriptions this week, including Hanbang Technology, Weigao Blood Purification, and Taili Technology, indicating a growing interest in innovative companies within the healthcare and technology sectors [1] Group 1: Hanbang Technology - Hanbang Technology is a leading supplier of chromatography separation and purification equipment in China, particularly in the production-grade small molecule drug separation market, holding a market share of approximately 39.2% [3] - The company has developed a comprehensive product matrix for both small and large molecule drug separation and purification equipment, catering to industrial production and laboratory research [2] - Hanbang Technology's revenue for 2022, 2023, and 2024 is projected to be 482 million, 619 million, and 691 million yuan, respectively, with net profits of 39 million, 51 million, and 79 million yuan [3] Group 2: Weigao Blood Purification - Weigao Blood Purification focuses on the research, production, and sales of medical products for blood purification, with a diverse product line including blood dialysis machines and accessories [4] - The company holds a leading market share in the domestic blood dialysis sector, with 32.5% in blood dialysis devices and 31.8% in blood dialysis tubing [4] - Revenue projections for Weigao Blood Purification for 2022, 2023, and 2024 are 3.426 billion, 3.532 billion, and 3.604 billion yuan, respectively, with net profits of 315 million, 442 million, and 449 million yuan [5] Group 3: Taili Technology - Taili Technology specializes in new material research and vacuum technology applications, being the exclusive supplier of compression bags for China's aerospace sector [6] - The company has implemented a multi-channel sales strategy, transitioning from traditional distribution to a primarily online sales model, while also maintaining strong offline retail partnerships [7] - Revenue forecasts for Taili Technology for 2022, 2023, and 2024 are 638 million, 835 million, and 1.02 billion yuan, respectively, with net profits of 59 million, 85 million, and 88 million yuan [7]

Core Viewpoint - The article discusses the upcoming IPOs of three companies in the A-share market, highlighting their business models, market positions, and financial projections. Group 1: Hanbang Technology - Hanbang Technology is a leading supplier of chromatography separation and purification equipment in China, particularly in the production-grade small molecule drug separation market [2][3] - The company has a diverse product matrix, including small and large molecule drug separation equipment, and has established a strong customer base with over 2,000 clients, including major pharmaceutical companies [4] - Financial projections indicate revenues of 482 million yuan, 619 million yuan, and 691 million yuan for 2022, 2023, and 2024 respectively, with net profits of 39 million yuan, 51 million yuan, and 79 million yuan [4] Group 2: Weigao Blood Purification - Weigao Blood Purification focuses on the research, production, and sales of medical products for blood purification, with a comprehensive product line including hemodialysis devices and peritoneal dialysis solutions [6][7] - The company holds significant market shares in various segments, including 32.5% in hemodialysis devices and 31.8% in hemodialysis tubing, ranking first in the industry [6][7] - Revenue projections for Weigao indicate 3.426 billion yuan, 3.532 billion yuan, and 3.604 billion yuan for 2022, 2023, and 2024 respectively, with net profits of 315 million yuan, 442 million yuan, and 449 million yuan [7] Group 3: Taili Technology - Taili Technology specializes in new materials and vacuum technology applications, being the exclusive supplier of aerospace vacuum compression bags in China [8][9] - The company has implemented a multi-channel sales strategy, transitioning to a primarily online sales model while maintaining partnerships with major retailers globally [9] - Financial forecasts show revenues of 638 million yuan, 835 million yuan, and 1.02 billion yuan for 2022, 2023, and 2024 respectively, with net profits of 59 million yuan, 85 million yuan, and 88 million yuan [10]

Group 1 - The "Private Economy Promotion Law" was passed, marking the first foundational law specifically for the development of the private economy in China, effective from May 20, 2025. It addresses key concerns such as "fair competition," "investment and financing promotion," "technological innovation," "business regulation," "service guarantee," and "rights protection" for private enterprises [1] Group 2 - The Ministry of Commerce noted that the U.S. has expressed willingness to negotiate on tariff issues, and China is currently evaluating this situation [2] Group 3 - A new proactive fiscal policy is set to be introduced in 2024, including a one-time increase of 6 trillion yuan in local special bond limits to replace hidden debts, issuance of special government bonds to support state-owned banks, and measures to stabilize the real estate market [3] Group 4 - In April, the manufacturing PMI fell to 49.0%, a decrease of 1.5 percentage points from the previous month, while the non-manufacturing PMI remained in the expansion zone at 50.4% [4] Group 5 - The U.S. President announced a 100% tariff on all films produced abroad entering the U.S., indicating a significant trade policy shift [5] Group 6 - U.S. non-farm payrolls increased by 177,000 in April, exceeding market expectations, while the unemployment rate remained stable at 4.2%. This led to a decrease in market expectations for a rate cut by the Federal Reserve [6] Group 7 - Global risk assets saw a comprehensive rise, with the Hang Seng Tech Index leading with a 3.1% increase, indicating a recovery trend in Chinese assets [7] Group 8 - The Hong Kong Monetary Authority intervened by purchasing 46.539 billion HKD in U.S. dollars to maintain the currency peg, marking its first intervention in five years [8] Group 9 - The Hong Kong Monetary Authority attributed the recent strength of the Hong Kong dollar to increased demand related to stock investments and the appreciation of several regional currencies against the U.S. dollar [9] Group 10 - Berkshire Hathaway's annual shareholder meeting addressed trade policies and investment strategies, emphasizing the importance of global trade [10] Group 11 - New energy vehicle companies reported significant growth in April deliveries, with XPeng Motors seeing a 273% year-on-year increase [11] Group 12 - Travel booking platform Fliggy reported an over 80% increase in customized travel bookings for the May Day holiday, indicating a shift towards more personalized travel experiences [12] Group 13 - OPEC+ announced an increase in production by 411,000 barrels per day starting in June, reflecting a response to current market conditions [13] Group 14 - Upcoming new stock offerings include three companies, with specific details on their subscription codes [14] Group 15 - CITIC Securities indicated that risk appetite is expected to rise in May, focusing on themes related to technology and consumption [15] Group 16 - Zhongtai Securities highlighted that opportunities in May will be more pronounced in technology, consumption, and certain cyclical sectors, suggesting a focus on improving performance and policy support [16]

Group 1: US-China Trade Relations - The Chinese Ministry of Commerce is currently evaluating the ongoing US-China trade dialogue, emphasizing that any negotiations must be based on the US correcting its unilateral tariff measures [2] - The Chinese stance remains firm: they are open to talks but will not tolerate coercive tactics from the US [2] Group 2: US Tariff Policies - President Trump announced a 100% tariff on all movies produced abroad entering the US, while suggesting that a trade agreement may be possible soon [3] - Trump downplayed concerns about the long-term negative impact of his tariff policies on the US economy [3] Group 3: Currency Movements - The Chinese yuan appreciated significantly during the May Day holiday, recovering nearly 900 points against the US dollar, attributed to several factors including positive signals from US-China trade talks and strong domestic travel data [4] - The Hong Kong Monetary Authority intervened by purchasing USD to defend the Hong Kong dollar's peg, marking its first intervention since 2020 [4] Group 4: Chinese Asset Performance - Chinese assets outperformed globally during the holiday, with the Hang Seng Tech Index rising by 3.1% and major tech stocks like Xiaomi and Alibaba seeing significant gains [5] - Global markets also showed positive trends, with major US and European indices recovering from previous losses [5] Group 5: Berkshire Hathaway's Financial Performance - Berkshire Hathaway reported a net profit of $4.603 billion for Q1 2025, a 64% decline year-on-year, with investment losses amounting to $5.038 billion [6] - The company's cash position reached a record high of $347.7 billion, indicating a strong liquidity position despite recent losses [6] Group 6: Buffett's Insights - Warren Buffett emphasized the importance of trade and expressed a need for the US to engage more with global markets, while also highlighting the transformative potential of AI [7] - Buffett announced plans for Greg Abel to succeed him as CEO, marking a significant leadership transition for Berkshire Hathaway [7] Group 7: Fiscal Policy Developments - China's Finance Minister outlined plans for a more proactive fiscal policy, with a target deficit rate of 4% for 2025, the highest in recent years [8] - The government plans to issue 11.86 trillion yuan in new bonds, focusing on investment promotion and support for key sectors [9] Group 8: Market Developments - The Beijing Stock Exchange may soon see its first delisted stock, as a company faces an audit opinion that could lead to its designation as a special treatment stock [10] - The upcoming Federal Reserve meeting is anticipated to maintain current interest rates, with market focus on potential comments from Chairman Powell [11] Group 9: IPO and Stock Unlocking - The China Securities Regulatory Commission approved an IPO for Shandong Xintong Electronics, with several new stocks set to be issued this week [12] - A total of 51 companies will have their restricted shares unlocked this week, with a combined market value of approximately 49.2 billion yuan [14]

刚过去的交易周（4月28日~4月30日）恰逢五一小长假前夕，当周仅有三个交易日，A股发生了显著变化。 如我们在4月30日推送的文章中所提及，4月最后一个交易日，以科技股为代表的高弹性股票走强，银行、保险、电力等防御性资产继续调整。因此，4月 最后一个交易周，不同风格指数表现迥异。沪深300指数当周下跌0.43%，科创50上涨0.78%，显示资金加速向高弹性赛道倾斜。 尤其是最后两个交易日，市场活跃度明显提升。上周一（4月28日），涨停家数为53家，涨幅超过7%个股共计77家；上周二（4月29日），涨停家数增加 至76只，涨幅超过7%个股增加至135只；上周三（4月30日），涨停家数进一步增加至100只，涨幅超过7%个股增加至168只。 五一小长假后首个交易周，A股只有4个交易日。节后市场将怎么走？我们先来看看外围市场在A股休市期间的表现。 假期外围股市集体反弹 美股方面，得益于贸易战缓和迹象和强劲非农就业报告，上周五（5月2日）标普500指数连续第九个交易日收高，创下自2004年以来最长连涨走势，并收 复了特朗普4月初宣布全面加征关税后的全部跌幅。 港股亦走强。5月2日港股正常开盘，恒生指数以大涨1.74%报 ...

钛媒体App 5月4日消息，下周（5月5日-11日）市场大事预告： 1．Wind数据显示，下周(5月5日至9日)央行公开市场将有16178亿元逆回购到期，其中5月6日、5月7日 分别到期10870亿元、5308亿元。 2．周二（6日）中国4月财新服务业PMI；中国4月财新综合PMI。 3．Wind数据显示，下周将有3只新股发行，其中沪市主板有1只，创业板有1只，合计发行约9020.94万 股，预计合计募资27.56亿元。具体来看，5月7日发行的是汉邦科技；5月8日发行的是威高血净、太力 科技。港股方面，博雷顿5月7日上市，沪上阿姨和钧达股份5月8日上市。 4．据同花顺iFinD数据，5月5日至11日A股共有50家公司限售股陆续解禁，合计解禁66.01亿股，按4月 30日收盘价计算，解禁总市值为491.34亿元。其中解禁市值居前三位的是天山股份（258.6亿元）、景嘉 微（44.3亿元）、嘉环科技（35.77亿元）。从个股解禁量看，解禁股数居前三位的是天山股份（52.88 亿股）、嘉环科技（2.18亿股）、康美药业（2.09亿股）。 5．周一（5日）美国4月Markit服务业PMI终值；美国4月ISM非制造业指 ...